Result of AGM

RNS Number : 5431P

Ergomed plc

10 June 2020

 

PRESS RELEASE

Results of 2020 Annual General Meeting

Guildford, UK - 10 June 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting ('AGM') held earlier today.  All resolutions were duly passed.

Details of the voting by way of a poll at the AGM in respect of each resolution are shown in the table below:

Resolution number	Votes for	Votes against	Abstentions
1	40,377,405	755,572	26,824
2	41,074,246	84,305	1,250
3	41,121,902	37,899	Nil
4	41,148,702	9,849	1,250
5	34,189,991	6,044,148	925,662
6	40,732,147	426,404	1,250
7	36,281,712	4,878,089	Nil
8	33,049,246	8,109,305	1,250
9	33,049,891	8,109,910	Nil

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav  Reljanović  (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Sue Stuart	[e-mail]
Matthew Neal / Olivia Manser

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit:  http://ergomedplc.com .

 

END

 

 

RAGFIFEARFIILII